These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32434381)

  • 21. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
    Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial.
    Raungaard B; Jensen LO; Tilsted HH; Christiansen EH; Maeng M; Terkelsen CJ; Krusell LR; Kaltoft A; Kristensen SD; Bøtker HE; Thuesen L; Aarøe J; Jensen SE; Villadsen AB; Thayssen P; Veien KT; Hansen KN; Junker A; Madsen M; Ravkilde J; Lassen JF;
    Lancet; 2015 Apr; 385(9977):1527-35. PubMed ID: 25601789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes.
    Menown IBA; Mamas MA; Cotton JM; Hildick-Smith D; Eberli FR; Leibundgut G; Tresukosol D; Macaya C; Copt S; Slama SS; Oldroyd KG
    J Interv Cardiol; 2021; 2021():6654515. PubMed ID: 33880087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
    Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
    Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of diabetes on 1-year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial.
    Hansen KN; Maeng M; Raungaard B; Engstrøm T; Veien KT; Kristensen SD; Ellert-Gregersen J; Jensen SE; Junker A; Kahlert J; Jakobsen L; Christiansen EH; Jensen LO
    Catheter Cardiovasc Interv; 2022 Mar; 99(4):1095-1103. PubMed ID: 35043539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
    Kaiser C; Galatius S; Jeger R; Gilgen N; Skov Jensen J; Naber C; Alber H; Wanitschek M; Eberli F; Kurz DJ; Pedrazzini G; Moccetti T; Rickli H; Weilenmann D; Vuillomenet A; Steiner M; Von Felten S; Vogt DR; Wadt Hansen K; Rickenbacher P; Conen D; Müller C; Buser P; Hoffmann A; Pfisterer M;
    Circulation; 2015 Jan; 131(1):74-81. PubMed ID: 25411159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial.
    Lee JM; Park SD; Lim SY; Doh JH; Cho JM; Kim KS; Bae JW; Chung WY; Youn TJ
    Trials; 2013 Nov; 14():398. PubMed ID: 24257456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial.
    Pilgrim T; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Heg D; Jüni P; Windecker S
    Am Heart J; 2014 Sep; 168(3):256-61. PubMed ID: 25173535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.
    van der Heijden LC; Kok MM; Zocca P; Jessurun GAJ; Schotborgh CE; Roguin A; Benit E; Aminian A; Danse PW; Löwik MM; Linssen GCM; van der Palen J; Doggen CJM; von Birgelen C
    Am Heart J; 2018 Apr; 198():25-32. PubMed ID: 29653644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
    Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial.
    Jakobsen L; Christiansen EH; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Madsen M; Raungaard B; Jensen SE; Christensen MK; Hansen HS; Jensen LO
    Am Heart J; 2018 Aug; 202():49-53. PubMed ID: 29807307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Muller O; Moarof I; Siontis GCM; Cook S; Weilenmann D; Kaiser C; Cuculi F; Hunziker L; Eberli FR; Jüni P; Windecker S
    Lancet; 2018 Sep; 392(10149):737-746. PubMed ID: 30170848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
    Iglesias JF; Heg D; Roffi M; Tüller D; Lanz J; Rigamonti F; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Valgimigli M; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2019 Nov; 8(22):e013607. PubMed ID: 31696762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.
    Yoon CH; Kwun JS; Choi YJ; Park JJ; Kang SH; Kim SH; Suh JW; Youn TJ; Kim MK; Cha KS; Lee SH; Hong BK; Rha SW; Kang WC; Lee JH; Kim SH; Chae IH
    Circ Cardiovasc Interv; 2023 Jan; 16(1):e012307. PubMed ID: 36475473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
    Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
    Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; van der Heijden LC; Kok MM; Danse PW; Schotborgh CE; Scholte M; de Man FHAF; Linssen GCM; von Birgelen C
    JAMA Cardiol; 2019 Jul; 4(7):659-669. PubMed ID: 31111862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.